预约演示
更新于：2025-02-14
Perampanel
吡仑帕奈
更新于：2025-02-14
概要
基本信息
药物类型 小分子化药 |
别名 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one、Perampanel Hydrate、BIOS2207 + [6] |
作用机制 AMPA receptor拮抗剂(离子型谷氨酸受体AMPA拮抗剂) |
非在研适应症 |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C23H15N3O |
InChIKeyPRMWGUBFXWROHD-UHFFFAOYSA-N |
CAS号380917-97-5 |
关联
150
项与 吡仑帕奈 相关的临床试验ChiCTR2400093593
Clinical efficacy analysis of perampanel in patients with epilepsy comorbid sleep disorders
CTR20243951
健康受试者在空腹及餐后状态下单次口服吡仑帕奈口服混悬液的人体生物等效性试验
CTR20243349
吡仑帕奈口服混悬液在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、两序列、双交叉空腹/餐后生物等效性试验
100 项与 吡仑帕奈 相关的临床结果
登录后查看更多信息
100 项与 吡仑帕奈 相关的转化医学
登录后查看更多信息
100 项与 吡仑帕奈 相关的专利（医药）
登录后查看更多信息
1,303
项与 吡仑帕奈 相关的文献（医药）2025-03-01EPILEPSY & BEHAVIOR
Cognitive and behavioral impact of antiseizure medications, neuromodulation, ketogenic diet, and surgery in Lennox-Gastaut syndrome: A comprehensive review
Review
作者: Samanta, Debopam
Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy marked by drug-resistant seizures and profound cognitive and behavioral impairments, with nearly 95% of individuals affected by moderate to severe intellectual disability. This review comprehensively explores the cognitive and behavioral impacts of current treatment options for LGS, including antiseizure medications (ASMs), neuromodulation strategies, the ketogenic diet, and surgical interventions. Given the limited availability of LGS-specific data for several ASMs, the evidence base is supplemented with findings from general epilepsy populations and individuals with epilepsy and intellectual disabilities. The evidence reveals that ASMs exert varied cognitive and behavioral effects in LGS. Medications such as valproate, lamotrigine, cannabidiol, fenfluramine, levetiracetam, brivaracetam, felbamate, and rufinamide generally support cognitive stability, while topiramate and zonisamide are associated with cognitive challenges. Behavioral outcomes also vary: stability is observed with valproate, lamotrigine, rufinamide, cannabidiol, and fenfluramine, whereas medications like levetiracetam, perampanel, brivaracetam, clobazam, and zonisamide can increase aggression or irritability. Nonpharmacological therapies, particularly when they reduce seizure frequency, typically provide greater cognitive and behavioral stability, with some offering improvement. Early intervention-especially through surgical options-appears most beneficial for preserving cognitive function. Additionally, therapies such as the ketogenic diet and neuromodulation may provide independent cognitive benefits beyond seizure control. This review emphasizes the importance of personalized treatment strategies, integrating cognitive and behavioral evaluations in therapy selection. Key components include baseline cognitive and behavioral assessments, followed by regular follow-up evaluations, particularly after therapy changes. Consideration of minimizing ASM polytherapy, careful evaluation of drug-drug interactions, pharmacogenomic implications, and the need for therapeutic drug monitoring in cases of cognitive adverse effects is essential. Future research should focus on developing assessment tools tailored to the unique needs of individuals with LGS, utilizing connectivity measures to assess intervention impacts, and advancing precision therapeutics to improve cognitive and behavioral outcomes.
2025-03-01EPILEPSY & BEHAVIOR
Cognitive and behavioral effects of perampanel 4 mg daily dose
Article
作者: Leeman-Markowski, Beth ; Gerard, Elizabeth ; Cunningham, Elizabeth ; King, Alexa ; Razavi, Babak ; Boyd, Alan ; Le, Scheherazade ; Falco-Walter, Jessica ; Li, Yi ; Graham, Edith ; Loring, David W ; Seliger, Jordan ; Meador, Kimford J
OBJECTIVE:
The neuropsychological adverse effects of antiseizure medications (ASMs) influence the tolerability, and in turn effectiveness of these medications, which can occur in a dose-dependent fashion. In this study, we examine the neuropsychological effects of perampanel (PER) at 4 mg daily as this dose has not been previously assessed with objective cognitive tests.
METHODS:
The study was originally designed to assess (1) effects of perampanel at 4 mg using different titration rates, and (2) habituation over time. Due to the COVID-19 pandemic, the study was halted, limiting the sample size needed to analyze titration and habituation effects. Therefore, we compared the neuropsychological effects of perampanel 4 mg daily from non-drug baseline to the end of drug titration and end of drug maintenance in this randomized double-blind study of healthy volunteers. Treatment period was 6 weeks total with 2 weeks of variable titration followed by 4-week maintenance. Composite Z-scores were calculated by combining Z-scores from both cognitive (computerized and non-computerized) and behavioral tests. Secondary analyses were conducted on the independent cognitive and behavioral domain Z-scores, and on the raw scores from 19 items in the full battery.
RESULTS:
The overall composite Z-scores did not differ across baseline, the end of titration, and the end of maintenance. Similarly, individual cognitive and behavioral domain Z-scores did not differ across the three titration rates. Exploratory analyses of the raw scores were marginally significant on only two of the 19 neuropsychological measures.
CONCLUSIONS:
Perampanel 4 mg daily was well tolerated with few neuropsychological effects in healthy volunteers.
2025-02-01BRAIN & DEVELOPMENT
Efficacy, safety, and tolerability of adjunctive perampanel in the treatment of pediatric patients aged 4–18 years with epilepsy: A single-center, retrospective, observational real-world study
Article
作者: Lin, Xi ; Ma, Bihong ; Rao, Xin ; Weng, Yijun
PURPOSE:
To observe the efficacy, safety, and tolerability of perampanel (PER) as add-on therapy in children aged 4-18 years with epilepsy in a real-world environment.
METHODS:
A single-center, retrospective, observational study was conducted at the First Affiliated Hospital of Fujian Medical University enrolling children with epilepsy aged 4-18 years who received PER as add-on therapy from January 2021 to November 2022 with 12 months of follow-up. Outcomes included 3-, 6- and 12-month retention, seizure freedom, responder rates, and adverse events (AEs) throughout follow-up.
RESULTS:
Seventy-eight children were included, of whom three were lost to follow-up. The responder rate at follow-up of 12 months was 54.7 %, the seizure-free rate was 32.0 % and the retention rate was 81.3 %. The number of seizures at baseline was a factor influencing the efficacy of the PER. Nine children reported AEs, with dizziness, drowsiness, and irritability being common.
CONCLUSIONS:
PER is safe, effective, and well tolerated for the treatment of children aged 4-18 years with epilepsy in clinical practice and is a potential option for refractory epilepsy. Patients with lower baseline seizure frequencies are more likely to exhibit a favorable response to PER.
100 项与 吡仑帕奈 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫部分性发作 | 欧盟 | 2012-07-23 | |
| 癫痫部分性发作 | 冰岛 | 2012-07-23 | |
| 癫痫部分性发作 | 列支敦士登 | 2012-07-23 | |
| 癫痫部分性发作 | 挪威 | 2012-07-23 | |
| 癫痫 | 欧盟 | 2012-07-23 | |
| 癫痫 | 冰岛 | 2012-07-23 | |
| 癫痫 | 列支敦士登 | 2012-07-23 | |
| 癫痫 | 挪威 | 2012-07-23 | |
| 特发全身性癫痫 | 欧盟 | 2012-07-23 | |
| 特发全身性癫痫 | 冰岛 | 2012-07-23 | |
| 特发全身性癫痫 | 列支敦士登 | 2012-07-23 | |
| 特发全身性癫痫 | 挪威 | 2012-07-23 | |
| 强直阵挛性癫痫 | 欧盟 | 2012-07-23 | |
| 强直阵挛性癫痫 | 冰岛 | 2012-07-23 | |
| 强直阵挛性癫痫 | 列支敦士登 | 2012-07-23 | |
| 强直阵挛性癫痫 | 挪威 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 欧盟 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 冰岛 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 列支敦士登 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 挪威 | 2012-07-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Lennox-Gastaut综合征 | 临床3期 | 美国 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 日本 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 澳大利亚 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 比利时 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 捷克 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 印度 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 韩国 | 2016-12-13 | |
| 癫痫发作 | 临床3期 | 美国 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 阿根廷 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 巴西 | 2008-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 12 | (Perampanel + Electrocorticography) | 蓋願齋遞鬱餘醖廠簾淵(鏇繭鑰醖觸築衊鑰簾窪) = 糧製廠窪築壓衊壓鏇餘 顧廠鑰願齋選鬱築壓艱 (選蓋齋鏇範繭網構憲鏇, 艱鹹構築蓋艱觸淵鑰獵 ~ 觸餘糧膚襯艱壓蓋夢積) 更多 | - | 2024-08-05 | ||
Levetiracetam (Standard of Care + Electrocorticography) | 蓋願齋遞鬱餘醖廠簾淵(鏇繭鑰醖觸築衊鑰簾窪) = 淵夢製艱艱淵憲構壓醖 顧廠鑰願齋選鬱築壓艱 (選蓋齋鏇範繭網構憲鏇, 繭獵積膚獵衊簾觸觸壓 ~ 鏇積糧繭觸鏇餘鏇繭鏇) 更多 | ||||||
临床4期 | 7 | (Fycompa 4 mg Daily) | 衊艱醖衊夢築憲壓獵構(獵簾夢夢鬱壓選繭膚憲) = 窪顧衊壓鏇鏇醖蓋淵製 壓鬱鑰遞窪選鑰鹹壓憲 (觸鹽選窪衊衊鬱獵觸夢, 艱網構鬱糧網糧鬱蓋膚 ~ 鹹窪獵觸淵積構獵積壓) 更多 | - | 2024-07-31 | ||
(Fycompa 4 mg Daily With a Boost to 6 mg Daily) | 衊艱醖衊夢築憲壓獵構(獵簾夢夢鬱壓選繭膚憲) = 壓膚範網夢願鏇襯齋襯 壓鬱鑰遞窪選鑰鹹壓憲 (觸鹽選窪衊衊鬱獵觸夢, 積餘齋廠餘廠範鑰餘鹹 ~ 鹹獵餘齋網襯憲鑰鬱醖) 更多 | ||||||
N/A | 56 | 憲願醖襯遞鏇齋網積廠(憲鑰鹹餘網夢襯獵鹽製) = reported by 14 subjects 齋糧廠夢築齋廠獵鏇醖 (築襯憲構繭膚憲網衊簾 ) | 积极 | 2024-06-28 | |||
N/A | 183 | Perampanel as add-on therapy | 鹹齋繭壓夢壓積蓋蓋膚(製窪夢簾膚齋壓廠夢夢) = 選構鑰鏇糧壓積鹹廠衊 選積鹹觸蓋夢鹽鹽鏇鹹 (醖獵膚餘窪廠鬱鏇觸鏇 ) 更多 | 积极 | 2024-06-28 | ||
Perampanel as substitution therapy | 鹹齋繭壓夢壓積蓋蓋膚(製窪夢簾膚齋壓廠夢夢) = 範獵範衊膚鏇憲壓衊鏇 選積鹹觸蓋夢鹽鹽鏇鹹 (醖獵膚餘窪廠鬱鏇觸鏇 ) 更多 | ||||||
临床4期 | 29 | Placebo (Placebo) | 醖鑰襯壓遞鏇製鏇餘夢(顧窪繭淵構膚襯遞鏇醖) = 鏇蓋繭簾鹹選繭鹽鑰憲 窪觸淵製膚簾網遞築窪 (衊積構積艱構鑰獵鏇襯, 壓膚蓋夢齋製鬱構衊願 ~ 製醖構鹹窪鬱製構壓夢) 更多 | - | 2024-06-06 | ||
(PER 1 Week Titration) | 醖鑰襯壓遞鏇製鏇餘夢(顧窪繭淵構膚襯遞鏇醖) = 範餘繭遞獵觸鹹網範壓 窪觸淵製膚簾網遞築窪 (衊積構積艱構鑰獵鏇襯, 獵願壓顧築鹽鏇構蓋蓋 ~ 齋窪簾淵鏇鹽廠築顧鹽) 更多 | ||||||
N/A | - | 12 | 窪簾齋鏇糧膚顧積鹹積(鏇夢網淵壓壓積廠鏇廠) = 網憲艱顧糧網醖憲壓淵 餘積夢顧淵窪鏇糧積遞 (簾築鑰艱鹹網鹹顧壓膚, 54) | 不佳 | 2024-04-09 | ||
窪簾齋鏇糧膚顧積鹹積(鏇夢網淵壓壓積廠鏇廠) = 憲艱繭夢簾構鑰鏇簾醖 餘積夢顧淵窪鏇糧積遞 (簾築鑰艱鹹網鹹顧壓膚, 54) | |||||||
临床4期 | - | 297 | 繭顧築壓積壓憲襯廠壓(糧壓繭鏇鹹鑰艱鏇鑰積) = 4.9% 蓋淵構願積製廠觸積鏇 (選願獵膚蓋選製遞鬱繭 ) 更多 | 积极 | 2023-10-01 | ||
临床4期 | - | 324 | 齋獵觸遞網鏇鹽衊艱網(鏇鹹壓選選構選襯衊鏇) = 4.9% 糧網鏇製簾積遞構廠夢 (艱製鹹鑰構範繭膚夢窪 ) 更多 | 积极 | 2023-09-04 | ||
N/A | 癫痫持续状态 追加 | - | 壓願獵網糧構鹹積壓夢(糧鏇壓憲觸鏇膚繭築襯) = 構鏇窪糧選鹽願鏇餘憲 鹹積築艱夢餘夢窪顧齋 (蓋簾積窪鑰範獵齋遞積 ) 更多 | 积极 | 2023-09-04 | ||
N/A | - | 艱醖壓鹹網襯蓋積鏇鏇(糧衊艱夢願構廠憲鬱襯) = 艱醖網築願淵糧範願範 網夢顧構範簾糧壓廠衊 (壓願獵醖餘醖蓋網齋網 ) 更多 | - | 2023-09-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用